Treatment Outcomes of Multidrug-Resistant Gram-Negative Bacterial Infections Treated with Ceftazidime-Avibactam in Severely Burned Patients with Sepsis
Main Article Content
Abstract
Objective: To evaluate the antimicrobial susceptibility of multidrug-resistant Gram-negative bacteria to ceftazidime-avibactam and the clinical outcomes of ceftazidime-avibactam therapy in severely burned patients with sepsis.
Subjects and methods: Thirty-four clinical specimens obtained from severely burned patients yielding multidrug-resistant Gram-negative bacteria (P. aeruginosa and K. pneumoniae) underwent antimicrobial susceptibility testing using multidrug-resistance card. Forty-nine patients with sepsis treated in the Intensive Care Unit, suspected or confirmed to be infected with P. aeruginosa or K. pneumoniae, received ceftazidime-avibactam either empirically or according to antimicrobial susceptibility results.
Results: P. aeruginosa demonstrated the highest susceptibility to ceftazidime-avibactam (61.11%), which was higher than that to ceftolozane-tazobactam (27.78%) and imipenem-relebactam (27.78%). Among the novel β-lactam/β-lactamase inhibitor combinations (N-BL/BLIs), ceftazidime-avibactam showed the highest susceptibility rate against K. pneumoniae (56.25%). The minimum inhibitory concentrations of ceftazidime-avibactam and imipenem-relebactam against P. aeruginosa and K. pneumoniae were the lowest among the N-BL/BLIs tested.
Among the 49 patients with sepsis, 91.84% developed septic shock. The predominant pathogen was P. aeruginosa (69.23% of blood culture isolates and 90.91% of wound culture isolates). The median duration of ceftazidime-avibactam therapy in burn patients with sepsis was 9 days. The mortality rate was 61.22%.
Conclusion: P. aeruginosa and K. pneumoniae remained highly susceptible to ceftazidime-avibactam. The mortality rate among burn patients with sepsis treated with ceftazidime-avibactam was 61.22%.
Keywords
Burns, sepsis, ceftazidime-avibactam
Article Details
References
2. Lê Quốc Vương, Nguyễn Như Lâm, Trần Đình Hùng và cộng sự. Đặc điểm nhiễm khuẩn đa kháng kháng sinh trên bệnh nhân bỏng nặng. Tạp chí Y học Việt Nam 2026; 560(3):87-92; https://doi.org/10.51298/vmj.v560i3.17944.
3. Martin K, Arif F, Sultan-Ali I et al. Analysis of ceftazidime/avibactam use for treating carbapenem-resistant infections in critically ill patients with thermal or inhalation injuries. Journal of Burn Care Research 2022; 43(4):759-765.
4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-810.
5. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012; 18(3):268-281.
6. Bassetti M, Vena A, Sepulcri C et al. Treatment of bloodstream infections due to Gram-negative bacteria with difficult-to-treat resistance. Antibiotics 2020; 9(9):632.
7. Blomquist KC, Nix DE. A critical evaluation of newer β-lactam antibiotics for treatment of Pseudomonas aeruginosa infections. Annals of Pharmacotherapy 2021; 55(8):1010-1024.
8. Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C et al. Selection of AmpC β-lactamase variants and metallo-β-lactamases leading to ceftolozane/tazobactam and ceftazidime/avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections. Antimicrobial Agents and Chemotherapy 2022; 66(2):e02067-02021.
9. Shields RK, Kline EG, Squires KM et al. In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors. JAC-Antimicrobial Resistance 2023; 5(5):dlad107.
10. Megdiche Z, Lamloumi M, Maamar B et al. In vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa: Results from a trauma center and burn unit in Tunisia. Annals of Burns and Fire Disasters 2025; 38(1):31-37.
11. Conil J-M, Georges B, Ravat F et al. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Clinical therapeutics 2013; 35(10):1603-1612.
12. Herbin SR, Barber KE, Isaacson AR et al. When more is still not enough: a case of ceftazidime-avibactam resistance in a burn patient. Journal of burn care & research 2022; 43(2):474-478.